The Latest Breaking News from Lung Disease

Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), the study met its primary endpoint for both the 50mg and 28mg EFX dose groups. Akero Therapeutics shares…

Theodore Wingate Dicks suffers from chronic lung disease, tracheomalacia, brain damage and an open duct in his heart, and medics have been unable to find a specific cause for the two-year-old's health issues.

More than 1.3 million people in the UK suffer from COPD

Researchers say 55% of COPD patients suffering two or more acute attacks a year earn under £20,000, with the poorest five times more likely to die from the condition

The FDA has approved Beyond Air Inc's (NASDAQ:XAIR) LungFit PH to treat term and near-term neonates with hypoxic respiratory failure (often referred to as persistent pulmonary hypertension of the newborn or PPHN).  LungFit PH is the initial device from the LungFit therapeutic platform of nitric oxide generators. It is the first FDA-approved product…

Monday marks the start of Love You Lungs week, a campaign to raise awareness of lung health. A lung condition can be permanent but there are treatments to slow down progression.

Exercise to help COPD hospital patients is being rolled out across Kyrgyzstan and to neighbouring countries

Beyond Air Inc (NASDAQ:XAIR) announced new interim data from the ongoing LungFit GO pilot at-home study in Australia. In this study, patients self-administered high concentration inhaled nitric oxide (NO) at home to treat severe nontuberculous mycobacterial (NTM) lung disease.  These data were shared at the American Thoracic Society International Conference 2022.  The company…

Patients suffering from a lung disease that blocks airways are almost 25 times more likely to develop severe COVID-19, Sydney scientists have found.